Freenome colorectal cancer test data improve on earlier results

The new study results could make Abbott, which has an agreement with Freenome to market the blood-based test, the dominant player in colorectal cancer screening, Evercore ISI analysts said.

By Susan Kelly • July 13, 2026

Q32 bounces back to claim study success for alopecia drug

Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations. 

By Jonathan Gardner • July 13, 2026

Explore the Trendline➔

Radiopharmaceuticals

A series of technological advances have led to an explosion of scientific progress — and dealmaking — involving medicines that can precisely deliver radioactive materials into tumors.   

By BioPharma Dive staff

GSK, Hansoh ADC extends survival in lung cancer study

GSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers. 

By Delilah Alvarado • July 10, 2026

Roche scraps two Ionis-partnered Huntington’s drugs

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of a second drug was scrapped because of a safety signal in animal testing.

By Jonathan Gardner • July 9, 2026

HHS plan to speed drug research won’t remove ‘self-inflicted’ delays

U.S. clinical trials continue to lose ground to China, but is Operation Trialblazer enough to help America catch up?

By Kelly Bilodeau • July 9, 2026

AstraZeneca, Ionis drug fails big heart disease study in major setback

Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and boosted the outlook of rival drugs from Alnylam and BridgeBio Pharma.

By Ben Fidler • July 9, 2026

Kailera says obesity pill succeeds in late-stage trial in China

The drug spurred about 10% weight loss over 10 months, though that finding came alongside high rates of gastrointestinal side effects that “alarmed” one analyst.

By Jonathan Gardner • July 7, 2026

Beyond Boston: Unlikely cities stake biotech claims

As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.

By Alexandra Pecci • July 6, 2026

BridgeBio gets funding for drug launch; United buys into cell therapy

Elsewhere, Otsuka’s kidney drug hit the goal of a confirmatory trial and Vertex’s CRISPR sickle cell drug secured expanded approval.

By BioPharma Dive staff • July 1, 2026

Abivax shares surge as worries subside over immune drug’s cancer risk

According to Abivax, fresh data suggest malignancy rates in its trials were no higher than "background" ones for people with ulcerative colitis, clearing a key safety concern.

By Jonathan Gardner • July 1, 2026

10 clinical trials to watch in the second half of 2026

The biotechnology sector’s upswing accelerated in the first half. Positive results from anticipated trials in lung cancer, Alzheimer’s and multiple autoimmune conditions could add to the momentum.

By BioPharma Dive staff • June 29, 2026

FDA accepts Replimune filing; Merck KGaA drops $11B on life sciences services

Replimune’s application is the latest example of changing attitudes at the FDA. Elsewhere, Revolution Medicines outlined more RAS-blocking data and a Definium stock offering brought in $800 million.

By BioPharma Dive staff • June 26, 2026

On second try, Acadia drug gets nod from European regulators

The influential CHMP committee also threw its support behind more than a dozen other medicines while recommending the marketing authorization for Tavneos be revoked.

By Jonathan Gardner • June 26, 2026

Pfizer drug acquired in Seagen deal disappoints in lung cancer study

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are optimistic about the drug’s chances in another trial.

By Delilah Alvarado • June 23, 2026

HHS, responding to China’s rise, moves to fast-track early drug research

A series of newly planned reforms are designed to entice companies to start early trials in the U.S. rather than overseas.

By Jonathan Gardner • June 23, 2026

Edgewise heart drug passes key trial test

Still, the results leave somewhat unclear how different the company’s drug is than marketed hypertrophic cardiomyopathy medicines from Bristol Myers Squibb and Cytokinetics.

By Jonathan Gardner • June 16, 2026

Lilly scores early positive data for new JAK drug

Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Incyte’s Jakafi.

By Jacob Bell • June 15, 2026

J&J multiple myeloma drug gains edge in earlier stage disease

The latest results studying Talvey in combination with Darzalex Faspro support J&J’s efforts to expand the immunotherapy's use.

By Delilah Alvarado • June 15, 2026

Planning a successful pivot from lab to clinic

For sterile injectables, key early decisions can have a significant impact on the products’ development.

June 15, 2026

Celiac disease is entering a new era of therapeutic innovation

For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.

By Paul Lizzul, M.D., Ph.D. • June 15, 2026

Novartis RNA drug acquired in $12B Avidity deal notches a trial win

The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.

By Gwendolyn Wu • June 11, 2026

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test

The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy. 

By Jonathan Gardner • June 11, 2026

Merck, Gilead report mixed outcomes in key lung cancer, HIV studies

Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.

By Delilah Alvarado • June 9, 2026

Tango data add to growing momentum for pancreatic cancer drugs

A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.

By Jonathan Gardner • June 8, 2026

ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other competing treatments.

By Ben Fidler • June 8, 2026